Belzutifan is an innovative drug for von Hippel-Lindau (VHL) syndrome, and its unique indications and mechanism of action provide a new treatment option for patients with VHL syndrome. This article will take a closer look at what Belzutifan is and how it interacts with each other.

What is the medicine belzutifan?

Belzutifan is an innovative drug, and its R&D background and indications have attracted much attention.

R&D background and manufacturer

Belzutifan is developed and manufactured by Merck & Co., Inc., and is an inhibitor of HIF-2α. The drug inhibits the growth and development of the disease in patients with VHL syndrome by inhibiting the activity of HIF-2α.

Indications and dosage

Belzutifan is indicated for the treatment of adult patients with VHL syndrome who require treatment of concomitant renal cell disease, central nervous system hemangioblastoma, or pancreatic neuroendocrine disease, but surgery is not required for the time being. The recommended dose is 120 mg orally once daily until disease progression or unacceptable toxicity.

Traits and storage

Belzutifan tablets are blue, oval-shaped, film-coated, and embossed with "177" on one side. The drug should be stored at 20 ° C - 25 ° C with an expiration date of 24 months.

Belzutifan is an innovative drug developed and manufactured by Merck & Co., Inc. in the United States, mainly for the treatment of specific diseases in patients with VHL syndrome. It is important for both patients and physicians to understand its R&D background, indications, dosage, and properties and storage.

Drug interactions with Belzutifan(Welireg)

When using Belzutifan, it is important to understand its interaction with other drugs to avoid potential adverse reactions and ensure drug safety.

Interaction with UGT2B17 or CYP2C19 inhibitors

Concomitant use of Belzutifan with UGT2B17 or CYP2C19 inhibitors is not recommended because these inhibitors may increase the blood concentration of begogetidan and thus increase the risk of adverse effects.

Interaction with CYP3A4 substrates

Belzutifan is also not recommended for concomitant use with sensitive CYP3A4 substrates, as Belzutifan may inhibit the activity of CYP3A4 enzymes, thereby affecting the metabolism and excretion of these substrates.

Interactions with hormonal contraceptives

Women of childbearing potential should avoid hormonal contraceptives during Belzutifan and for 1 week after the last dose, as Belzutifan may render some hormonal contraceptives ineffective. These women are advised to use effective non-hormonal contraceptives during this period.

When using Belzutifan, patients should pay close attention to its interactions with other drugs. Avoid concomitant use with UGT2B17 or CYP2C19 inhibitors, sensitive CYP3A4 substrates, and hormonal contraceptives to ensure drug safety and reduce potential adverse effects.